---
title: "DUALITYBIO appoints Chief Financial Officer"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/280236792.md"
description: "DUALITYBIO-B announced the appointment of Zhang Shaoren as the company's Chief Financial Officer, effective from the day before (23rd)"
datetime: "2026-03-24T01:22:36.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280236792.md)
  - [en](https://longbridge.com/en/news/280236792.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280236792.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/280236792.md) | [English](https://longbridge.com/en/news/280236792.md)


# DUALITYBIO appoints Chief Financial Officer

DUALITYBIO-B (09606.HK) announced the appointment of Zhang Shaoren as the company's Chief Financial Officer, effective from the day before (23rd)

### 相關股票

- [ChinaAMC SSE STAR Biology and Medicine ETF (588130.CN)](https://longbridge.com/zh-HK/quote/588130.CN.md)
- [Sutro Biopharma (STRO.US)](https://longbridge.com/zh-HK/quote/STRO.US.md)
- [DUALITYBIO-B (09606.HK)](https://longbridge.com/zh-HK/quote/09606.HK.md)
- [ICBCCS SSE STAR Biology and Medicine ETF (588860.CN)](https://longbridge.com/zh-HK/quote/588860.CN.md)
- [Direxion S&P Biotech Bull 3X (LABU.US)](https://longbridge.com/zh-HK/quote/LABU.US.md)
- [ChinaAMC CSI Biotechnology Theme ETF (516500.CN)](https://longbridge.com/zh-HK/quote/516500.CN.md)
- [China Merchants CSI Biotechnology Theme ETF (159849.CN)](https://longbridge.com/zh-HK/quote/159849.CN.md)
- [Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF (159506.CN)](https://longbridge.com/zh-HK/quote/159506.CN.md)
- [Guotai CSI Bio-medicine ETF (512290.CN)](https://longbridge.com/zh-HK/quote/512290.CN.md)
- [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-HK/quote/BIB.US.md)
- [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/zh-HK/quote/IBBQ.US.md)
- [Tianhong CNI BIOMEDICINE ETF (159859.CN)](https://longbridge.com/zh-HK/quote/159859.CN.md)
- [Minsheng Royal CSI Biotechnology Theme ETF (516930.CN)](https://longbridge.com/zh-HK/quote/516930.CN.md)
- [China Southern Hang Seng Biotech ETF(QDII) (159615.CN)](https://longbridge.com/zh-HK/quote/159615.CN.md)
- [E Fund Hang Seng SCHK Innovative Drug ETF (159316.CN)](https://longbridge.com/zh-HK/quote/159316.CN.md)
- [ChinaAMC Hang Seng Biotechnology Technology ETF(QDII) (159892.CN)](https://longbridge.com/zh-HK/quote/159892.CN.md)
- [Yinhua CSI Innovative Drugs Industry ETF (159992.CN)](https://longbridge.com/zh-HK/quote/159992.CN.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-HK/quote/IBB.US.md)
- [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-HK/quote/XBI.US.md)
- [Bosera Hang Seng SCHK Innovative Drug Select ETF (520690.CN)](https://longbridge.com/zh-HK/quote/520690.CN.md)
- [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-HK/quote/FBT.US.md)
- [Hwabao WP Hang Seng SCHK Innovative Drug Select ETF (520880.CN)](https://longbridge.com/zh-HK/quote/520880.CN.md)
- [Penghua SSE STAR Biology and Medicine ETF (588250.CN)](https://longbridge.com/zh-HK/quote/588250.CN.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-HK/quote/BBH.US.md)
- [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-HK/quote/ARKG.US.md)
- [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-HK/quote/SBIO.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-HK/quote/PBE.US.md)
- [Huaan Hang Seng Biotech ETF (159102.CN)](https://longbridge.com/zh-HK/quote/159102.CN.md)
- [E Fund CSI Biotechnology Theme ETF (159837.CN)](https://longbridge.com/zh-HK/quote/159837.CN.md)

## 相關資訊與研究

- [Junshi Biosciences Chairman Completes RMB100 Million Shareholding Increase](https://longbridge.com/zh-HK/news/281231901.md)
- [UCB presents new Bimzelx data at AAD](https://longbridge.com/zh-HK/news/280813909.md)
- [Sunho Biologics Flags Audit Delays as Auditor Seeks More Documentation](https://longbridge.com/zh-HK/news/280992698.md)
- [3SBio Nearly Doubles Revenue and Quadruples Profit in 2025, Keeps Dividend Steady](https://longbridge.com/zh-HK/news/281054154.md)
- [Innovent Biologics says FY IFRS revenue rmb13.04 billion](https://longbridge.com/zh-HK/news/280622281.md)